WO2017209072A1 - Article absorbant - Google Patents

Article absorbant Download PDF

Info

Publication number
WO2017209072A1
WO2017209072A1 PCT/JP2017/019967 JP2017019967W WO2017209072A1 WO 2017209072 A1 WO2017209072 A1 WO 2017209072A1 JP 2017019967 W JP2017019967 W JP 2017019967W WO 2017209072 A1 WO2017209072 A1 WO 2017209072A1
Authority
WO
WIPO (PCT)
Prior art keywords
wrap sheet
absorbent article
absorbent
core wrap
core
Prior art date
Application number
PCT/JP2017/019967
Other languages
English (en)
Japanese (ja)
Inventor
祐一 廣瀬
暁 湯山
良輔 山崎
繁宏 松原
佑佳 鈴木
雅史 小栗
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016111620A external-priority patent/JP6228629B1/ja
Priority claimed from JP2017103981A external-priority patent/JP6887878B2/ja
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201780016535.XA priority Critical patent/CN108778206A/zh
Publication of WO2017209072A1 publication Critical patent/WO2017209072A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad

Definitions

  • the present invention relates to an absorbent article for menstrual blood absorption.
  • Patent Document 1 discloses a menstrual band including an absorbent pad containing a salt of multivalent ions.
  • Patent Document 2 discloses a napkin containing a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent.
  • Patent Document 3 proposes a personal care absorbent article containing a triblock polymer or polycation containing polypropylene oxide and polyethylene oxide as a fluid treatment material.
  • the present invention includes a liquid-permeable surface sheet disposed on the skin facing surface side, a liquid-impermeable back sheet disposed on the non-skin facing surface side, and an absorber disposed between these two sheets.
  • the present invention relates to an absorbent article for absorbing blood.
  • the said absorber has an absorptive core containing a pulp fiber, and a core wrap sheet
  • a water-soluble hemagglutinating agent is disposed on the core wrap sheet that covers the skin facing surface side of the absorbent core.
  • the present invention also includes a liquid-permeable surface sheet disposed on the skin facing surface side, a liquid-impermeable back sheet disposed on the non-skin facing surface side, and an absorber disposed between these two sheets.
  • the present invention relates to an absorbent article for absorbing menstrual blood.
  • the said absorber has an absorptive core containing a pulp fiber, and a core wrap sheet
  • a water-soluble cationic polymer is held in the core wrap sheet covering the skin-facing surface side of the absorbent core in a state where the pores of the core wrap sheet are filled.
  • the cationic polymer is dissolved, and voids in the pores are increased.
  • FIG. 1 is a plan view of a sanitary napkin which is an embodiment of the absorbent article of the present invention.
  • FIG. 2 is a cross-sectional view taken along line II-II in FIG.
  • FIG. 3A is an electron microscope (SEM) photograph of a core wrap sheet in which a hemagglutinating agent is held in a state where the pores are filled
  • FIG. 3B is a blood cell on the core wrap sheet. It is an electron microscope (SEM) photograph which shows the state before hold
  • FIG. 4 is an enlarged cross-sectional view of an absorbent body showing a preferred configuration of the absorbent body of the absorbent article of the present invention.
  • FIG. 4 is an enlarged cross-sectional view of an absorbent body showing a preferred configuration of the absorbent body of the absorbent article of the present invention.
  • FIG. 5 is an enlarged cross-sectional view of an absorbent body showing another preferred configuration of the absorbent body of the absorbent article of the present invention.
  • FIG. 6 is an enlarged cross-sectional view of an absorbent body showing still another preferred configuration of the absorbent body of the absorbent article of the present invention.
  • FIG. 7 (a) is an electron microscope (SEM) photograph of the core wrap sheet used in Examples 1 and 2 before the hemagglutinating agent is applied, and FIG. 7 (b) is an application of the hemagglutinating agent.
  • FIG. 7C is an electron microscope (SEM) photograph of the core wrap sheet used in Examples 1 and 2 after being constructed, and FIG. 7C shows that the hemagglutinating agent is held in a state in which the pores are filled. It is an electron microscope (SEM) photograph after water-permeable (after first-time water permeability) to the core wrap sheet used in Examples 1 and 2.
  • Patent Documents 1 and 4 do not disclose the application state of the fluid treatment agent in the absorbent article, except that a water-soluble metal compound is used as the blood coagulant, thereby improving the blood absorption rate and the absorption amount. There is no description about the configuration to be performed.
  • the absorbent articles described in Patent Document 2 and Patent Document 3 can agglutinate red blood cell components, but menstrual blood that is continuously discharged is absorbed later in the menstrual mass by the aggregate formed in the initial stage.
  • fluid treatment agents containing polycations can be used, only data on nonionic treatment materials are disclosed.
  • red blood cell clots are trapped between fibers of a nonwoven web.
  • the present invention relates to an absorbent article in which the effect of improving the absorption performance by the hemagglutinating agent is expressed more effectively.
  • the napkin 1 includes a liquid-permeable top sheet 2 disposed on the skin facing surface side, a liquid-impermeable back sheet 3 disposed on the non-skin facing surface side, and both A liquid retaining absorbent 4 disposed between the sheets 2 and 3 is provided.
  • the top sheet 2, the absorber 4 and the back sheet 3 are integrated to form an absorbent main body 5.
  • Side leakproof sheets 6 are arranged on the surface sheet 2 side on both sides in the longitudinal direction of the absorbent main body 5.
  • the side leak-proof sheet 6 has a free end 61 that is not joined to the top sheet 2 and a fixed end 62 that is joined to the top sheet 2, and is used between the fixed end 62 and the free end 61 when used.
  • a main body adhesive portion (not shown) used for fixing to the crotch portion of the shorts is provided on the non-skin facing surface of the absorbent main body 5.
  • the napkin 1 has a pair of wing part 7 in the both sides in the vertical direction X corresponding to a wearer's front-back direction.
  • a wing adhesive portion (not shown) used for fixing the crotch portion of the shorts to the non-skin facing surface is provided.
  • the heat seal part may be provided in the whole periphery of absorbent articles, such as the napkin 1.
  • the napkin 1 includes an excretory part facing part B that is disposed to face the excretion part (such as the vaginal opening) of the wearer when worn, and the abdomen (front side) of the wearer than the excretion part facing part B ) And a rear portion C disposed closer to the wearer's back side (rear side) than the excretory portion facing portion B.
  • the napkin 1 has a longitudinal direction X corresponding to the wearer's front-rear direction and a transverse direction Y orthogonal to the longitudinal direction X. That is, the napkin 1 is divided into the front part A, the excretion part opposing part B, and the rear part C in this order in the vertical direction X.
  • a skin opposing surface is a surface in the napkin 1 or its component (for example, surface sheet 2, absorptive core 41) orient
  • the facing surface is a surface of the napkin 1 or its constituent members that is directed to the side opposite to the skin side (usually the clothing side) when the napkin 1 is worn.
  • the excretory part facing part B is a so-called wing part like the napkin 1 of the present embodiment, and in the longitudinal direction X of the absorbent article, It is a region having a pair of wing portions on both the left and right sides, and more specifically, means a region sandwiched between a root along the longitudinal direction X of one wing portion and a root along the longitudinal direction X of the other wing portion. .
  • two folding lines that cross the absorbent article in the transverse direction Y which are generated when the absorbent article is folded into a tri-fold individual form.
  • region enclosed by the 1st folding line and the 2nd folding line is counted from the front end of the longitudinal direction X of this absorbent article.
  • the top sheet 2 covers the entire area of the skin 4 of the absorbent body 4, and the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4.
  • the surface sheet 2 and the back surface sheet 3 are joined to each other at the extended portions from both end edges in the longitudinal direction X of the absorber 4.
  • the back sheet 3 and the side leak-proof sheet 6 are joined to each other at portions extending outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorber 4. In this way, the absorbent body 4 is sandwiched between the top sheet 2 and the back sheet 3.
  • any joining means such as an adhesive, heat sealing, ultrasonic sealing or the like is used.
  • the napkin 1 is provided with a linear leak-proof groove 8 in which the top sheet 2 and the absorber 4 are integrally recessed toward the back sheet 3 side. Therefore, in the leak-proof groove 8, the density of each fiber that is a constituent member with respect to the top sheet 2 and the absorbent body 4 is higher than the density of the peripheral portion of the leak-proof groove 8.
  • “Linear” in the linear leak-proof groove 8 means that the shape of the leak-proof groove 8 that is a recessed portion is not limited to a straight line in a plan view but includes a curved line. Each line may be a continuous line or a discontinuous line such as a broken line.
  • the leak-proof groove 8 may be composed of a row formed by a number of discontinuous point embosses.
  • the absorbent body 4 of the napkin 1 has an absorbent core 41 containing pulp fibers and a core wrap sheet 42 that covers the absorbent core 41.
  • the core wrap sheet 42 in the present embodiment has a skin side portion 42a (hereinafter also referred to as a skin side core wrap sheet) covering the skin facing surface side of the absorbent core 41 and a non-skin facing surface side of the absorbent core 41. It has a non-skin side portion 42b (also referred to as a non-skin side core wrap sheet) that is wound down and covers the non-skin facing surface side of the absorbent core 41.
  • seat 42 has the overlapping part 42c of a sheet
  • seat in this invention may wrap the whole absorptive core with one sheet
  • the skin facing surface side and the non-skin facing surface side of the absorbent core 41 may be covered with separate sheets.
  • the core wrap sheet 42 of this embodiment contains a water-soluble hemagglutinating agent. More specifically, in the core wrap sheet 42 of the present embodiment, the skin-side core wrap sheet 42a is a hemagglutinating agent placement portion containing a hemagglutinating agent. Furthermore, in the core wrap sheet 42 of the present embodiment, in addition to the skin-side core wrap sheet 42a being a hemagglutinating agent placement portion containing a hemagglutinating agent, the non-skin-side core wrap sheet 42b is made of a hemagglutinating agent.
  • the hemagglutinating agent placement portion may be included, and the hemagglutinating agent placement portion may be formed so as to cover the skin-side core wrap sheet 42a, the absorbent core 41, and the non-skin-side core wrap sheet 42b.
  • the skin-side core wrap sheet 42a only needs to have a hemagglutinating agent placement portion containing a hemagglutinating agent, and the non-skin-side core wrap sheet 42b has a hemagglutinating agent.
  • the placement unit may not exist.
  • a core wrap sheet is used for the purpose of improving the shape retention of an absorbent core that is insufficient in shape retention alone or preventing leakage of the constituent material of the absorbent core.
  • a fiber sheet such as a nonwoven fabric is used.
  • the core wrap sheet 42 of the present embodiment has pores between fibers in the skin facing surface, the non-skin facing surface, and the region in the thickness direction located therebetween in a state where the hemagglutinating agent is not disposed.
  • the hole portion has a structure communicating in the thickness direction.
  • a network structure of inter-fiber voids in which the inter-fiber voids are three-dimensionally complicatedly formed is formed by the communicating pores.
  • the absorbent article in the present invention is provided with a core wrap sheet 42 that holds such a hole portion filled with a water-soluble hemagglutinating agent.
  • the hemagglutinating agent fills the pores on the skin facing surface side of the skin side core wrap sheet 42a.
  • a hemagglutinating agent is held in a state in which the pores on the non-skin facing surface side 422 (the side in contact with the absorbent core 41) of the skin side core wrap sheet 42a are filled. It is also possible to use a skin-side core wrap sheet 42a in which the pores on the skin facing surface side 421 and the non-skin facing surface side 422 in contact with the absorbent core 41 are filled.
  • the skin facing surface side of the core wrap sheet 42 is divided into three sections by dividing the core wrap sheet 42 (skin-side core wrap sheet 42a) into three in the thickness direction.
  • the layer closest to the skin is preferred.
  • the non-skin facing surface side of the core wrap sheet 42 is divided into three sections in the thickness direction when the core wrap sheet 42 (skin-side core wrap sheet 42a) is divided into three sections. It is preferably the layer farthest from the wearer's skin.
  • sheets such as air-through nonwoven fabric, spunbond nonwoven fabric, and urethane foam sheet can be used as the core wrap sheet 42.
  • FIG. 3A is an electron microscope (SEM) photograph of the core wrap sheet in which the hemagglutinating agent is held in a state where the pores of the core wrap sheet 42 are filled
  • FIG. It is an electron microscope (SEM) photograph which shows the state before making the lap sheet
  • SEM electron microscope
  • the ratio of the area filled with the hemagglutinating agent (occlusion rate) when the total area of the pores is at least 100% in the pores on the hemagglutinating agent disposition surface is such as menstrual blood
  • the occlusion rate by the hemagglutinating agent in the core wrap sheet 42 is 10% or more from the viewpoint of sufficiently dissolving the hemagglutinating agent when moisture such as menstrual blood passes through the core wrap sheet. Preferably, 15% or more is more preferable. Further, from the viewpoint of efficiently dissolving the hemagglutinating agent, the occlusion rate is preferably 100% or less, and more preferably 95% or less.
  • the ratio of the volume filled with the hemagglutinating agent (volume occlusion rate) in the pores forming a three-dimensionally connected network structure in the thickness direction is the core wrap sheet
  • volume occlusion rate volume occlusion rate
  • the volume occlusion rate is preferably 10% or more, and more preferably 15% or more. Further, from the viewpoint of efficiently dissolving the hemagglutinating agent, the occlusion rate is preferably 90% or less, and more preferably 70% or less. In this case, when the core wrap sheet 42 is cut in order to observe the cross section, and the cut surface is observed with an SEM, both the area occupied by the pores and the area of the hemagglutinating agent buried in the image are analyzed. By quantifying with, it is possible to measure the hole blockage rate.
  • the hemagglutinating agent is formed between fibers and fibers in the pores on the skin facing surface side 421 of the skin-side core wrap sheet 42a. It is preferable to fill the pores so as to stretch the film between them. Being buried so as to stretch the membrane means that the hemagglutinating agent is present across the plurality of fibers facing the pores in the core wrap sheet 42. To do.
  • the pores of the core wrap sheet 42 are three-dimensionally communicated in the thickness direction by the hemagglutinating agent. More preferably, there are pores that are buried in a non-existent state.
  • menstrual blood permeates through the core wrap sheet 42 from the skin facing surface side to the non-skin facing surface side in the thickness direction of the fiber sheet in a state where the hemagglutinating agent is not three-dimensionally communicated in the thickness direction. It is always preferable in that it involves dissolution of the hemagglutinating agent.
  • the core wrap sheet 42 in the present invention has pores between the fibers, and the pores communicate with each other in the thickness direction.
  • gap between fibers connected in a three-dimensionally complicated manner by the part is used.
  • the resin film which has a communicating hole part connected in the thickness direction can also be used.
  • the “core wrap sheet” refers to a sheet in a state before the hemagglutinating agent is contained.
  • the core wrap sheet 42 is preferably a sheet made of cellulosic fibers from the viewpoint that the hemagglutinating agent efficiently fills the pores.
  • the core wrap sheet 42 of the present embodiment is preferably a sheet composed of cellulosic fibers, and the basis weight is preferably 10 g / m from the viewpoint of liquid permeability, hardness, and pore size. 2 or more, more preferably 13 g / m 2 or more, preferably 30 g / m 2 or less, more preferably 20 g / m 2 or less.
  • the core wrap sheet 42 of the present embodiment is mainly manufactured by a wet papermaking method, but may be manufactured by a dry method such as airlaid.
  • Examples of the cellulose fibers constituting the core wrap sheet 42 of the present embodiment include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers.
  • Examples of cellulosic fiber pulp include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or straw pulp. These cellulosic fibers can be used singly or in combination of two or more. Further, from the viewpoint of improving the strength, a small amount of non-cellulosic fibers can be mixed.
  • Examples of non-cellulosic fibers include polyolefin fibers such as polyethylene and polypropylene, and condensation fibers such as polyester and polyamide.
  • the proportion of the cellulosic fibers in the constituent fibers of the thin paper is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • a nonwoven fabric can also be used as the core wrap sheet 42.
  • the nonwoven fabric there are pores between the fibers, and the pores communicate with each other in the thickness direction, and the voids between the fibers are three-dimensional due to the communicated pores. If the network structure of inter-fiber gaps that are intricately linked to each other is formed, non-woven fabrics produced by various manufacturing methods can be used.For example, spunbond nonwoven fabrics, meltblown nonwoven fabrics, and high-speed water stream treatment entangle the constituent fibers of the fiber web.
  • a spunlace nonwoven fabric which is a nonwoven fabric obtained by heating, an air-through nonwoven fabric, which is a nonwoven fabric obtained by thermally fusing constituent fibers of a fiber web by hot air treatment, and a nonwoven fabric obtained by adhering constituent fibers of a fiber web with an adhesive.
  • a resin bond nonwoven fabric etc. are mentioned.
  • the fiber web of spunlace nonwoven fabric, air-through nonwoven fabric, and resin bond nonwoven fabric can be manufactured by a card machine or an airlaid method in which fibers are stacked in air.
  • Non-woven fabric fibers are made from cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers and cellulose acetate, polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and synthetic resins such as polyamides such as nylon.
  • the synthetic fiber which becomes is mentioned.
  • As the synthetic fiber a core-sheath type or side-by-side type composite fiber may be used. Among these, for the same reason as the use of thin paper, it is preferable that the raw material fibers are cellulosic fibers even in the case of nonwoven fabrics of various production methods.
  • the proportion of the cellulosic fibers in the constituent fibers of the nonwoven fabric is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • the raw material fiber of a nonwoven fabric can be used individually by 1 type or in combination of 2 or more types.
  • a resin film having a communicating hole portion communicating in the thickness direction used as the core wrap sheet 42 of the present embodiment
  • a resin film having a through hole can be used.
  • the diameter of the through hole is preferably 0.2 mm or greater and 4.0 mm or less, and more preferably 0.5 mm or greater and 2.5 mm or less.
  • the number of through holes is preferably about 10 to 50 per 1 cm square.
  • the method for retaining the hemagglutinating agent in the core wrap sheet 42 of the present embodiment is not particularly limited as long as it can be retained so as to fill the pores, but it is dissolved in an appropriate solvent and various physical properties such as viscosity are appropriately adjusted. It is preferable to dry or remove the solvent after adhering or immersing as a solution in the core wrap sheet 42 from the viewpoint of easily maintaining the hemagglutinating agent in the pores of the core wrap sheet 42.
  • the solvent is not particularly limited as long as it can dissolve the hemagglutinating agent. For example, water can be used conveniently.
  • the solvent is highly volatile from the viewpoint of shortening the drying time of the solution and thereby unevenly distributing the hemagglutination on the coated surface side.
  • the solvent is preferably an organic solvent that can dissolve the hemagglutinating agent.
  • organic solvents include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, acetone, tetrahydrofuran, acetonitrile, N, N-dimethylformamide, dimethyl sulfoxide, acetic acid and formic acid.
  • These organic solvents can be used individually by 1 type or in combination of 2 or more types. Alternatively, one or more of these organic solvents can be used in combination with water. From the viewpoint of safety, high volatility, and economical efficiency, it is preferable to use ethanol.
  • the method of adhering the solution containing the hemagglutinating agent to the core wrap sheet 42 was based on the immersion of the solution, spray coating, dipping method, transfer method, die coating, gravure coating, ink jet method, screen printing method, and printing. Examples thereof include liquid application to a predetermined portion of the absorber 4 using a known liquid coating apparatus such as coating, and these can be used freely.
  • the spray coating method efficiently fills the pores by appropriately adjusting the shape of the spray nozzle, the amount of application, and the like of a solution containing a hemagglutinating agent in which various physical properties such as viscosity are appropriately adjusted. It is preferable because it can be maintained in a state.
  • the drying may be any of drying by heating, drying by reduced pressure, and drying combining heating and reduced pressure, but may be natural drying instead of forced drying. Drying by heating, from the viewpoint of fixing the core wrap sheet 42 in a filled state, in a range where the hemagglutinating agent and the core wrap sheet are not damaged, drying is performed by rapidly removing the solvent. It is more preferable to do.
  • the core wrap sheet 42 in the napkin 1 of the present embodiment preferably has a pH of the water extract measured by the JIS method (JIS P 8133-1: 2013) from the viewpoint of fixing the pores in a filled state. Is 3.5 or more, more preferably 6.0 or more, preferably 9.0 or less, more preferably 8.0 or less, and preferably 3.5 or more and 9.0 or less, more preferably 6 It is 0.0 or more and 8.0 or less.
  • the core wrap sheet 42 in the napkin 1 of the present embodiment is configured such that the hemagglutinating agent dissolves when the water permeates through the core wrap sheet 42 and the voids in the core wrap sheet 42 are increased. Yes. This occurs because the hemagglutinating agent is held in a state where the pores are filled, and the hemagglutinating agent dissolves and disappears from the pores when moisture passes through the pores. That is, when the hemagglutinating agent completely fills and closes the pores, voids are generated from a state where there is no void due to dissolution of the hemagglutinating agent. Further, in the case where some voids are present in a part of the pores that are filled with the hemagglutinating agent, the volume of the voids is expanded by dissolution of the hemagglutinating agent.
  • menstrual blood has passed through the core wrap sheet 42 in use because the hemagglutinating agent at the time of water solubility is held in the core wrap sheet 42 that covers the absorbent core 41.
  • the hemagglutinating agent dissolves in the menstrual blood held in the pores, and red blood cells aggregate due to the action of the hemagglutinating agent in the boundary between the core wrap sheet 42 and the absorbent core 41 or in the absorbent core 41. To do.
  • menstrual blood is separated into erythrocyte aggregates and parts other than erythrocytes, and movement of erythrocyte aggregates is suppressed compared to parts other than erythrocytes, whereas parts other than erythrocytes It diffuses well in the absorbent core.
  • menstrual blood parts other than red blood cells are preferentially absorbed into the absorber 4.
  • a superabsorbent polymer when used, absorption inhibition due to accumulation of red blood cells on its surface is prevented.
  • menstrual blood is more reliably separated from the erythrocyte aggregates and absorbed by the superabsorbent polymer, so that red blood cells accumulate on the surface of the superabsorbent polymer. Absorption inhibition is less likely to occur.
  • the potential absorption performance which an absorptive core has is fully expressed by such an effect
  • the core wrap sheet 42 has a larger amount of hemagglutinating agent on the skin-facing surface side than in a state where the hemagglutinating agent is present uniformly throughout the layer. It is preferable from the viewpoint of more effectively filling the hole portion. “There are many on the skin facing surface side” means that the hemagglutinating agent is present more on the skin facing surface side than the non-skin facing surface side, and the hemagglutinating agent is present on the skin facing surface side. Includes a mode that does not exist on the non-skin facing surface side.
  • the hemagglutinating agent When the hemagglutinating agent fills the pores on the skin-facing surface side of the pores of the skin-side core wrap sheet 42a, the hemagglutinating agent dissolves by contact with menstrual water, It flows out to the skin facing surface side. Moreover, since menstrual blood is less likely to enter the core wrap sheet from the pores, menstrual blood spreads on the skin-facing surface, and the contact efficiency between the water in menstrual blood and the hemagglutinating agent is increased.
  • the hemagglutinating agent is dissolved in moisture and the force of moving from the skin facing surface of the skin side core wrap sheet 42a to the non-skin facing surface side works strongly, so that aggregates are formed at various thickness positions, Some are captured in the core wrap sheet and some are captured in the absorbent core. For this reason, although the network of interfiber gaps is partially blocked, the interfiber gaps are expanded in other portions, so that it is difficult to inhibit liquid permeability in repeated absorption of menstrual blood.
  • the core wrap sheet has a three-dimensional network structure of interfiber spaces, menstrual water in which the hemagglutinating agent is dissolved diffuses not only in the thickness direction but also in the plane direction.
  • the core wrap sheet In the core wrap sheet, a portion where the void portion is blocked by the aggregate and a void portion where the hemagglutinating agent is held coexist. For this reason, menstrual blood that has reached the core wrap sheet after a lapse of a certain time since the initial absorption of menstrual blood enters the core wrap sheet from the increased pores on the skin facing surface side, and the void portion of the three-dimensional network structure
  • the core wrap sheet can be moved via The hemagglutinating agent held in the void portion and menstrual blood contact each other, and the menstrual blood and the hemagglutinating agent move mainly in the thickness direction and the surface direction, and the aggregate and the hemagglutinating agent are mainly composed of water. Liquid component is produced.
  • a napkin capable of absorbing menstrual blood for a long time can be realized.
  • the leak-proof groove 8 and the hemagglutinating agent placement portion are arranged so as to overlap in plan view, moisture in menstrual blood becomes easy to concentrate on the leak-proof groove 8, and the above-described effects are further enhanced.
  • the present invention also includes the case where the hemagglutinating agent fills the pores on the non-skin facing surface side among the pores of the core wrap sheet 42.
  • a sanitary absorbent article capable of effectively absorbing menstrual blood can be obtained by a mechanism similar to the above-described mode in which the hemagglutinating agent fills the pores on the skin facing surface side of the core wrap.
  • the hemagglutinating agent fills the pores on the skin facing surface side of the core wrap.
  • this mechanism does not necessarily need to have the hemagglutinating agent arrangement
  • the hemagglutinating agent In order for the hemagglutinating agent to preferentially fill the pores on one side of the core wrap sheet, the hemagglutinating agent is included, and the viscosity when added to the core wrap sheet during application is preferably It is convenient to employ a method of adding a solution of 1 mPa ⁇ s or more to at least one surface of the core wrap sheet. In this case, the solution can be added only to one side of the core wrap sheet. However, this method is preferable because it can be applied to both sides so that the amount of the solution added is less on one side than on the other side.
  • the viscosity of the solution is more preferably 1 mPa ⁇ s or more at the time of application, and further preferably 3 mPa ⁇ s or more.
  • the upper limit of the viscosity is preferably 1000 mPa ⁇ s or less, and more preferably 100 mPa ⁇ s or less.
  • the viscosity of the solution containing the hemagglutinating agent is measured by the following method. Using a B-type viscometer TVB-10 manufactured by Toki Sangyo Co., Ltd., rotor No. It can be measured under measurement conditions of 19, 30 rpm, 25 ° C. and 60 seconds.
  • the core wrap sheet 42 is The second water transmission rate is preferably faster than the first water transmission rate.
  • the initial water transmission rate and the second water transmission rate are measured as follows. [Measurement method of the first and second permeation rates] Measurement of the first water transmission rate and the second water transmission rate was performed as shown in the figure.
  • a sample piece in which the liquid passage layer was cut to a length of 50 mm and a width of 50 mm was prepared, and then the sample piece was sandwiched and fixed from both the upper and lower sides with a glass tube having an inner diameter of 35 mm. At this time, the liquid is fixed from both sides with a clip through silicon rubber so that the liquid does not ooze out from the side during measurement.
  • 3 g of physiological saline as a measuring solution is taken into a 10 ml beaker and gently poured into the glass tube. After injecting physiological saline, the time required for the amount of water permeation (the amount of liquid permeated through the sample piece) to reach 2.3 g was measured, and this was taken as the initial liquid passage time (unit: seconds).
  • the initial water permeation rate (unit: g / second) was obtained by dividing 3 g by the initial liquid passage time. Allow to stand for 3 minutes as it is, and then gently inject the above 3 g of the measurement solution, and similarly determine the second liquid passage time (unit: seconds) and divide 2.3 g by the second liquid passage time.
  • the second water permeation rate (unit: g / second). About the above, it measured on the electronic balance.
  • the initial permeation rate and the second permeation rate measured by the above-described method are the ratio of the second permeation rate and the initial permeation rate (second permeation rate /
  • the first water transmission rate) is preferably 1.05 times or more, more preferably 1.5 times or more, preferably 150 times or less, more preferably 30 times or less, and preferably 1.05 times or more. 150 times or less, more preferably 1.5 times or more and 30 times or less.
  • the initial water transmission rate is preferably 0.01 g / second or more, more preferably 0.05 g / second or more, preferably 1.50 g / second or less, more preferably 0.70 g / second or less, Further, it is preferably 0.01 g / second or more and 1.50 g / second or less, more preferably 0.05 g / second or more and 0.70 g / second or less.
  • the second water permeation rate is preferably 0.25 g / second or more, more preferably 0.75 g / second or more, preferably 2.0 g / second or less, more preferably 1.5 g / second or less. Further, it is preferably 0.25 g / second or more and 2.0 g / second or less, more preferably 0.5 g / second or more and 1.5 g / second or less.
  • the core wrap sheet 42 In order for the core wrap sheet 42 to have a second permeation rate that is faster than the first permeation rate, the core wrap sheet 42 must have a physical property that starts dissolving within at least 3 minutes from when the hemagglutinating agent comes into contact with the liquid to be measured. It is preferable that the dissolution rate is high.
  • the skin-side core wrap sheet 42a preferably contains more hemagglutinating agent on the skin facing surface side 421 than on the non-skin facing surface side 422.
  • the hemagglutinating agent is preferably present only on the skin-facing surface side 421 of the skin-side core wrap sheet 42a.
  • the agglomerate existing part moves to the non-skin facing surface side of the skin side core wrap sheet 42a, and the skin facing side of the skin side core wrap sheet 42a.
  • the increased interfiber gap formed on the surface side promotes menstrual blood intake, and the plasma component separated by the hemagglutinating agent inside the skin-side core wrap sheet 42a easily reaches the absorbent core 41. Yes.
  • the absorptive core 41 of the napkin 1 of this embodiment is composed of a mixed product of pulp fibers and a superabsorbent polymer.
  • the mixed fiber stack is manufactured by a known drum-type fiber stacking apparatus including a stacking drum having a stacking concave portion on the peripheral surface, and is sucked from the bottom surface of the stacking concave portion, The surface is supplied with pulp fibers and superabsorbent polymer as the absorbent core forming material in a scattered state, and after the absorbent core forming material is deposited in the accumulation recess, it is released from the accumulation recess. Is obtained.
  • the absorbent core 41 of the napkin 1 of the present embodiment may be a single fiber stack of pulp fibers that does not contain a superabsorbent polymer.
  • Examples of the pulp fibers constituting the absorbent core 41 include cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate. These fibers can be used alone or in combination of two or more.
  • Examples of the raw material pulp of the pulp fiber include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or wall pulp.
  • the absorbent core 41 is made of synthetic fibers such as polyolefin fibers such as polyethylene and polypropylene, condensed fibers such as polyester and polyamide, in addition to pulp fibers made of cellulosic hydrophilic fibers. A small amount may be mixed.
  • the absorbent core in the present invention has a ratio of pulp fibers (cellulosic fibers), particularly wood pulp fibers, of preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less. Preferably it is 100 mass%.
  • the absorbent core 41 may contain a water-absorbing polymer.
  • a particulate polymer is generally used, but a fibrous polymer may be used.
  • the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape.
  • a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof.
  • sodium salts can be preferably used.
  • a copolymer obtained by copolymerizing the above-mentioned comonomer within a range that does not deteriorate the performance of the superabsorbent polymer.
  • water-absorbing polymer it is possible to more quickly absorb and retain a large amount of excretory fluid such as blood.
  • the hemagglutinating agent provided in the napkin 1 acts to agglutinate erythrocytes in blood to form aggregates and separate them from plasma components.
  • a preferred hemagglutinating agent when 1000 ppm is added to simulated blood, at least two or more red blood cells aggregate to form an aggregate in a state where the fluidity of the blood is maintained.
  • the state in which the fluidity of blood is maintained means that 10 g of blood to which a measurement sample is added at 1000 ppm is a screw tube bottle (product number “Screw tube No.
  • Simulated blood means that the viscosity measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) is 8 mPa ⁇ s.
  • the blood cell / plasma ratio of defibrinated horse blood was prepared.
  • the simulated blood to which the measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (manufactured by HORIBA, model number: LA-950V2, measurement condition: flow type).
  • the median diameter of volume average particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using cell measurement, circulation speed 1, no ultrasonic wave) corresponds to the size of an aggregate in which two or more red blood cells are aggregated. If it is 10 ⁇ m or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.
  • the hemagglutinating agent retained on the core wrap sheet 42 preferably contains a cationic polymer.
  • the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride.
  • the hemagglutinating agent can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer.
  • the hemagglutinating agent can also contain a low-molecular natural homopolymer such as polylysine as the cationic polymer.
  • the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution.
  • the “quaternary ammonium moiety” described below is also used in the same meaning and is a moiety that is positively charged in water.
  • the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things.
  • the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.
  • the hemagglutinating agent includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer
  • a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate may be included, or any combination of two or more thereof may be included. Also good.
  • a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types.
  • the quaternary ammonium salt copolymer can be used alone or in combination of two or more.
  • a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.
  • the “hemagglutinating agent” refers to the aggregation of erythrocytes by a single compound or a combination of single compounds capable of aggregating blood erythrocytes or a combination of a plurality of compounds. It is an agent that expresses. That is, the hemagglutinating agent is an agent limited to those having a hemagglutination effect.
  • the hemagglutinating agent contains the third component, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.
  • the term “single compound” is a concept including compounds having the same composition formula but having different molecular weights due to different numbers of repeating units.
  • quaternary ammonium salt polymer a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate
  • quaternary ammonium salt polymer a quaternary ammonium salt polymer that is quaternary ammonium salt of a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt in a quaternary ammonium salt polycondensate.
  • the quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.
  • the quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety.
  • a quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent.
  • the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce
  • the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate.
  • dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur.
  • the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. .
  • a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized.
  • Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.
  • Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • erythrocytes can be treated as colloidal particles having an anionic charge.
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.
  • the cationic polymer preferably has a molecular weight of 2000 or more, and more preferably 10,000 or more.
  • the molecular weight of the cationic polymer is not less than these values, the entanglement of the cationic polymers between the erythrocytes and the crosslinking of the cationic polymer between the erythrocytes are sufficiently caused.
  • the upper limit of the molecular weight is preferably 30 million or less, and more preferably 22 million or less.
  • the cationic polymer dissolves well into menstrual blood.
  • the molecular weight of the cationic polymer is preferably 2000 or more and 30 million or less, and more preferably 10,000 or more and 22 million or less from the viewpoint of enhancing the effect of suppressing the movement of blood beyond the aggregating agent disposition portion. preferable. Furthermore, when the molecular weight of the cationic polymer is 10,000 or more and 150,000 or less, particularly 10,000 or more and 120,000 or less, the aggregate of menstrual blood is not excessively enlarged and is generated in an appropriate size. In the absorbent core and core wrap sheet, it is suppressed that the agglomerates block the pulp fiber voids and voids in the core wrap sheet voids, and the cationic polymer dissolves well into menstrual blood. This is preferable because blood permeability is maintained high.
  • the molecular weight said to this invention is a weight average molecular weight.
  • the molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions.
  • the molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows. As the column, a column in which a guard column ⁇ and an analytical column ⁇ -M manufactured by Tosoh Corporation are connected in series is used at a column temperature of 40 ° C.
  • the detector uses RI (refractive index).
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 ⁇ L.
  • Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 ⁇ L.
  • the quaternary ammonium salt polymer has a flow potential of 1500 ⁇ eq / L or more from the viewpoint of more effectively generating red blood cell aggregates. , More preferably 2000 ⁇ eq / L or more, still more preferably 3000 ⁇ eq / L or more, still more preferably 4000 ⁇ eq / L or more.
  • the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized.
  • the upper limit of the streaming potential is preferably 13000 ⁇ eq / L or less, more preferably 8000 ⁇ eq / L or less, and even more preferably 6000 ⁇ eq / L or less.
  • the streaming potential of the quaternary ammonium salt polymer is preferably 1500 ⁇ eq / L or more and 13000 ⁇ eq / L, more preferably 2000 ⁇ eq / L or more and 13000 ⁇ eq / L or less, and 3000 ⁇ eq / L or more and 8000 ⁇ eq / L or less. Is more preferably 4000 ⁇ eq / L or more and 6000 ⁇ eq / L or less.
  • the flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituting cationic monomer itself, and the copolymerization molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. Can be controlled.
  • the streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, hot melt bonding each member to a commercially available napkin is invalidated using a dryer or the like, and decomposed into members such as a top sheet, an absorber, and a back sheet.
  • a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition.
  • the obtained solution was dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent.
  • the cationic polymer In order for the cationic polymer to be successfully adsorbed on the surface of red blood cells, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of red blood cells. From this point of view, the present inventors proceeded with studies, and as a result, inorganic value / organic value (hereinafter referred to as “IOB (Inorganic Organic Balance) value”), which is the ratio between the inorganic value and the organic value of the substance. It was found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of. Specifically, it has been found advantageous to use a cationic polymer having an IOB value that is the same as or close to that of the sialic acid conjugate.
  • the sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.
  • the properties of substances are largely governed by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Waals force due to molecular mass and electrical affinity due to molecular polarity. If each of Van Der Waals force and electrical affinity, which have a great influence on changes in the properties of substances, can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to.
  • This idea is a theory well known as “organic conceptual diagram”.
  • Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic.
  • the degree of physical properties due to Van Der Waals force is called “organic”, and the degree of physical properties mainly due to electrical affinity is called “inorganic”.
  • the physical properties of substances are considered as a combination of “organic” and “inorganic”.
  • one carbon (C) is defined as organic 20
  • the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value.
  • the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values
  • the IOB value of the cationic polymer is determined based on the value.
  • the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated.
  • polydiallyldimethylammonium chloride which is a cationic polymer used in Example 1 to be described later
  • an organic value of ⁇ C ⁇ ⁇ 8 160
  • an inorganic value of Ammo and NH4 salt ⁇ 1 400
  • it has an inorganic value of Ring (non-aromatic single ring) ⁇ 1 10
  • an organic value of ⁇ Cl ⁇ 1 40
  • the IOB value is calculated according to the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is ORA, the inorganic value is INA, the organic value of monomer B is ORB, and the inorganic value is INB. Yes, when the molar ratio of monomer A / monomer B is MA / MB, the IOB value of the copolymer is calculated from the following equation.
  • the IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, 2.2 It is still more preferable that it is above. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. More preferably, it is 2.2 or more and 3.0 or less.
  • the IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate.
  • the sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.
  • the organic value itself is preferably 40 or more, more preferably 100 or more, and even more preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, still more preferably 240 or less, and even more preferably 190 or less.
  • the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, still more preferably 100 or more and 240 or less, and still more preferably 130 or more and 190 or less.
  • the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and 250 or more. It is particularly preferred that Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less.
  • the inorganic value is preferably from 70 to 790, more preferably from 90 to 750, even more preferably from 90 to 680, still more preferably from 120 to 680, It is especially preferable that it is 250 or more and 490 or less.
  • x and y satisfy the following formula A when the organic value of the cationic polymer is x and the inorganic value is y.
  • y ax (A)
  • a is preferably 0.66 or more, more preferably 0.93 or more, and even more preferably 1.96 or more.
  • a is preferably 4.56 or less, more preferably 4.19 or less, and even more preferably 3.5 or less.
  • a is preferably a number from 0.66 to 4.56, more preferably from 0.93 to 4.19, and a number from 1.96 to 3.5. Is more preferable.
  • the organic value and the inorganic value of the cationic polymer satisfy the above formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above-mentioned ranges, the cation The functional polymer is likely to interact with the sialic acid conjugate, and the cationic polymer is more easily adsorbed to erythrocytes.
  • the cationic polymer is preferably water-soluble.
  • water-soluble means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mm ⁇ ) and mixed with 50 mL ion-exchanged water at 25 ° C.
  • a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd.
  • the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
  • the cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium moiety is preferably present in the side chain.
  • the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs.
  • bonded at one point means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain.
  • Connected at two or more points means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain.
  • a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto.
  • the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more.
  • the upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less.
  • the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less.
  • the carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included.
  • the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer
  • examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety.
  • a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization are examples of the homopolymer.
  • alkylating agent and the acid are as described above.
  • the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.
  • quaternary ammonium salt homopolymer examples include polyethyleneimine.
  • examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer
  • two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer.
  • a copolymer obtained by the above copolymerization can be used.
  • the quaternary ammonium salt copolymer one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety
  • the copolymer obtained by copolymerizing using 1 or more types of bodies can be used.
  • the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.
  • the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer
  • charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated.
  • Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine.
  • Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds.
  • nonionic polymerizable monomers examples include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate.
  • One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do.
  • a quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).
  • a polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety.
  • a polymerizable monomer having no quaternary ammonium moiety When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed.
  • the functional group capable of hydrogen bonding include —OH, —NH 2 , —CHO, —COOH, —HF, —SH and the like.
  • polymerizable monomers having functional groups capable of hydrogen bonding examples include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl An acrylate etc. are mentioned.
  • hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used.
  • a polymerizable monomer for copolymerization By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced.
  • functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups.
  • polymerizable monomers having functional groups capable of hydrophobic interaction examples include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned.
  • methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. Or it is preferable to adjust so that the streaming potential of a quaternary ammonium salt copolymer may become the value mentioned above. Or it is preferable to adjust so that IOB of a quaternary ammonium salt copolymer may become the value mentioned above.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and even more preferably 56 mol% or less.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate
  • a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used as the polycondensate.
  • Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.
  • the above-described quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or copolymerization method of a vinyl polymerizable monomer.
  • the polymerization method for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.
  • the cationic polymer described in detail above is an example of the above-mentioned “preferable hemagglutinating agent”, and the effect thereof is Japanese Patent Application No. 2015-239286, Japanese Patent Application Laid-Open No. 2016-107100, which is a Japanese publication of the application, and Reference can be made to Examples 1 to 45 described in International Publication No. 2016/093233 pamphlet of the international application based on the priority of the application.
  • the hemagglutinating agent retained on the core wrap sheet 42 is, for example, a composition containing a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, a skin care agent, etc. (hemagglutinating agent composition) ).
  • a solvent water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used.
  • glycerin polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used.
  • flavor the fragrance
  • an antibacterial / deodorant it is polymerized from a cancrinite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used.
  • the skin care agent plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.
  • the ratio of the hemagglutinating agent contained in the hemagglutinating sheet is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and further preferably 1% by mass or more. Further, it is preferably 50% by mass or less, more preferably 40% by mass or less, and further preferably 30% by mass or less.
  • the proportion of the hemagglutinating agent contained in the hemagglutinating sheet is preferably 0.1% by mass or more and 50% by mass or less, more preferably 0.5% by mass or more and 40% by mass or less, and 1% by mass. More preferably, it is 30 mass% or less.
  • the ratio of the hemagglutinating agent contained in the hemagglutinating sheet is measured by the following method.
  • the hemagglutinating sheet is immersed in water for 60 min to elute the hemagglutinating agent. Thereafter, the water from which the obtained hemagglutinating agent is eluted is dried and solidified. From the mass of the dried and solidified sample, the ratio of the hemagglutinating agent is determined.
  • the chemical structure of the hemagglutinating agent is identified by 1 H-NMR or mass spectrometry (MS) alone or in combination.
  • the proportion of the cationic polymer in the hemagglutinating agent is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less.
  • the proportion of the cationic polymer is preferably 1% by mass to 50% by mass, more preferably 3% by mass to 30% by mass, and even more preferably 5% by mass to 10% by mass. preferable.
  • the amount of the cationic polymer held on the core wrap sheet 42 is preferably 1 g / m 2 or more, more preferably 3 g / m 2 or more, and even more preferably 5 g / m 2 or more. Further, it is preferably 20 g / m 2 or less, more preferably 15 g / m 2 or less, and still more preferably 10 g / m 2 or less.
  • the amount of the cationic polymer is preferably 1 g / m 2 or more and 20 g / m 2 or less, more preferably 3 g / m 2 or more and 15 g / m 2 or less, and further preferably 5 g / m 2 or more and 10 g / m 2. More preferably, it is as follows. By applying the cationic polymer in an amount within this range, excreted menstrual red blood cells can be effectively aggregated.
  • the absorbent core 41 in the present invention includes a superabsorbent polymer 43, and the blending amount of the superabsorbent polymer 43 changes in the thickness direction of the absorbent core 41. It is also preferable. 4 to 6, in the core wrap sheet 42 covering the absorbent core 41, only the skin side portion 42a covering the skin facing surface side of the absorbent core 41 is provided with a hole portion. In the state where the hemagglutinating agent is retained in a state where the core is filled, the non-skin side portion 42b covering the non-skin facing surface side of the absorbent core 41 is similarly filled with the void portion of the core wrap sheet 42. A hemagglutinating agent may be retained.
  • a pulp layer 41A that contains pulp fibers and does not contain a superabsorbent polymer is present on the skin facing surface 41u side of the absorbent core 41, and is non-skin facing than the pulp layer 41A.
  • a mixed layer 41B having pulp fibers and a superabsorbent polymer 43 is provided on the surface 41d side.
  • the core wrap sheet 42 that holds the hemagglutinating agent and the superabsorbent polymer 43.
  • the distance between the erythrocyte and the time lag described above becomes longer, so that the part other than the erythrocyte is more reliably separated from the aggregate of erythrocytes, and is absorbed by the superabsorbent polymer. This further improves the absorption performance.
  • this configuration helps the core wrap sheet to have a second water permeation rate faster than the first water permeation rate.
  • a pulp layer 41C that contains pulp fibers and does not contain a superabsorbent polymer is present on the non-skin facing surface 41d side of the absorbent core 41.
  • a mixed layer 41B having pulp fibers and a superabsorbent polymer 43 is provided on the skin facing surface 41u side.
  • the pulp layer 41C which contains a pulp fiber and does not contain a superabsorbent polymer exists in the non-skin opposing surface 41d side of the absorbent core 41, and from the pulp layer 41C.
  • a mixed layer 41B having pulp fibers and a superabsorbent polymer 43 is provided on the skin facing surface 41u side.
  • a pulp layer 41 ⁇ / b> A that further contains pulp fibers and does not contain a superabsorbent polymer is also formed on the skin facing surface 41 u side of the absorbent core 41.
  • the mixing layer 41B immediately increases with the absorption of blood. Since blood can easily reach the absorbent polymer 43, it can be said that most of the superabsorbent polymer 43 is likely to contribute to improving the absorbent capacity of the absorbent core.
  • the mixed layer 41B causes the liquid to flow when the product is pressurized by the movement of the user.
  • the structure Since it has an effect of blocking, it can be said that the structure has excellent wet back properties.
  • the superabsorbent polymer 43 is present at a position close to the liquid excretion part. The phenomenon of reaching the polymer and preventing the effective absorption of blood has been manifested more remarkably.
  • the hemagglutinating agent on the skin side portion 42a of the core wrap sheet 42 absorbs most of the superabsorbent polymer 43 without causing weakening of the hemagglutinating agent effect, which is the aforementioned problem. It can be said that the structure is excellent in wet-back properties, and an absorbent article excellent in absorption performance is obtained. As described above, in both the configuration of FIG.
  • the hemagglutinating agent is held in a state in which the hole portion of the core wrap sheet 42 is filled, thereby improving the absorption performance such as wetback properties. Is expressed more effectively.
  • the absorber 4 shown in FIG. 6 both the effect when using the absorber shown in FIG. 4 and the effect when using the absorber shown in FIG. 5 are produced.
  • a hemagglutinating agent similar to the hemagglutinating agent held in the core wrap sheet is blended in the absorbent core 41 in addition to the core wrap sheet 42. This is because by arranging the hemagglutinating agent on the absorbent core, the aggregation speed can be further increased and the aggregation can be more strongly generated.
  • the arrangement mode of the hemagglutinating agent in the case where the hemagglutinating agent is disposed on the absorbent core 41 may not be a state in which the hole portion of the core wrap sheet 42 is filled.
  • the absorber shown in FIG. 4 or the absorber shown in FIG. 5 may be added to the pulp layer 41A or may be added to the mixed layer 41B.
  • the average pore diameter of the absorbent core 41 is larger than the average pore diameter of the core wrap sheet 42 from the viewpoint that the hemagglutinating agent is easily held in a state where the voids of the core wrap sheet 42 are filled.
  • This relationship may be satisfied for the skin-side core wrap sheet 42a, but the non-skin-side core wrap sheet 42b may be satisfied.
  • the core wrap sheet 42a and the absorbent are absorbed.
  • the average pore diameter of the core wrap sheet 42 is an average pore diameter measured in a state where the hemagglutinating agent is not held or not included or in a state where the hemagglutinating agent is completely dissolved.
  • the method for measuring the average pore diameter of the absorbent core and the average pore diameter of the core wrap sheet 42 is as follows.
  • the hole diameter in the measurement target part is observed with a scanning electron microscope (for example, JEM-6000 scanning electron microscope JCM-6000) at a magnification of 100 to 300 times, and has the largest diameter in contact with pulp fibers and sheet materials in the entire observation region.
  • Ten different regions are observed at random, and the average value of the ten inscribed circle diameters obtained from them is defined as the average pore diameter in the measurement target region.
  • the average pore diameter of the core wrap sheet 42 is preferably 10 ⁇ m or more, more preferably 30 ⁇ m or more, and preferably 150 ⁇ m or less, more preferably 100 ⁇ m or less.
  • the porosity of the core wrap sheet 42 is preferably 20% or more, more preferably 30% or more, and preferably 90% or less, more preferably 70%, from the viewpoint of maintaining the pores in a filled state. It is as follows.
  • the porosity is preferably 20% to 90%, more preferably 30% to 70%.
  • the ratio of the average pore diameter of the core wrap sheet 42 to the average pore diameter of the absorbent core is preferably 0.05 or more, more preferably 0.1 or more, and preferably 0.9 or less, more preferably 0. .5 or less.
  • the material for forming the napkin 1 described above will be described.
  • the top sheet 2, the back sheet 3, and the side leak-proof sheet 6, those normally used for absorbent articles such as sanitary napkins can be used without particular limitation. it can.
  • the back sheet 3 a liquid-impermeable or water-repellent resin film, a laminate of a resin film and a nonwoven fabric, or the like can be used.
  • the side leak-proof sheet 6 a laminated nonwoven fabric having a high water pressure resistance, a laminate of a resin film and a nonwoven fabric, or the like can be used.
  • the surface sheet 2 a single layer or multilayer nonwoven fabric, a perforated film, or the like can be used.
  • the top sheet 2 can be coated with various oil agents for improving liquid permeability, for example, various surfactants.
  • the topsheet 2 has a multilayer structure, the topsheet 2 includes a first fiber layer located on the side close to the wearer's skin and a second fiber layer located on the side far from the wearer's skin. And both fiber layers are integrated in the thickness direction by a number of joints formed in part, and a portion of the first fiber layer located between the joints is convex. It is possible to use a concavo-convex sheet that protrudes and forms the concavo-convex convex portion.
  • the convex portion of the concavo-convex sheet may have a solid structure that is entirely filled with fibers, or may have a hollow structure having a space inside.
  • the concavo-convex sheet in which the convex portion has a solid structure for example, those described in Japanese Patent Application Laid-Open Nos. 2007-182626 and 2002-187228 can be used.
  • the entire absorbent core 41 of the napkin 1 is formed by integral molding, but may not be integrally molded.
  • a pulp layer that includes pulp fibers and does not include a superabsorbent polymer, and a mixed layer that includes pulp fibers and a superabsorbent polymer 43 are laminated separately. The thing used as the absorptive core is mentioned.
  • the absorbent article may be one that does not have a side leak-proof sheet and a leak-proof mechanism thereby, and may not have a wing portion.
  • the napkin shown in FIG. 1 has the leak-proof groove 8 formed by embossing on the skin facing surface, the shape of the leak-proof groove can be changed as appropriate, and the leak-proof groove itself may be eliminated.
  • the absorbent article according to the present invention may be a sanitary napkin, a panty liner (clay sheet), or the like.
  • a liquid-permeable sheet containing a hemagglutinating agent is a core wrap sheet as a covering sheet that covers an absorbent core, and the hemagglutinating agent is a core. It is contained in the site
  • the hemagglutinating sheet has an uneven distribution of the hemagglutinating agent when viewed along its thickness direction, and the hemagglutinating agent is unevenly distributed on the non-skin facing surface side.
  • the advantages of the hemagglutinating agent being unevenly distributed on the non-skin facing surface side of the hemagglutinating sheet are as follows. As described above, when menstrual blood comes into contact with the hemagglutinating sheet, erythrocytes in the menstrual blood are aggregated by the action of the hemagglutinating agent to form an aggregate. The generated agglomerates are trapped between the meshes of fibers constituting the hemagglutinating sheet and accumulate in the sheet. As a result, clogging of the hemagglutinating sheet is likely to occur, and the decrease in menstrual permeability becomes significant with the number of menstrual blood absorption.
  • the tendency becomes more prominent as the molecular weight of the hemagglutinating agent increases.
  • the hemagglutinating agent is unevenly distributed on the non-skin-facing surface side of the hemagglutinating sheet, the agglomerates generated by the contact between menstrual blood and the hemagglutinating agent can easily flow out of the hemagglutinating sheet. .
  • clogging of the hemagglutinating sheet due to the formation of aggregates is less likely to occur.
  • the hemagglutinating sheet in which the hemagglutinating agent is unevenly distributed is disposed at a specific position of the napkin 1, thereby maintaining the menstrual blood absorption performance and resulting from the hemagglutinating agent.
  • clogging of the sheet due to the agglomerates generated is effectively prevented.
  • the hemagglutinating sheet has an amount W1 of hemagglutinating agent contained on the non-skin facing surface side and an amount W2 of hemagglutinating agent contained on the skin facing surface side.
  • the ratio W2 / W1 on a mass basis is preferably 45/55 or less, more preferably 40/60 or less, still more preferably 30/70 or less, and 27/73 or less. Is more preferably 20/80 or less, and most preferably 0/100 or more.
  • the ratio W2 / W1 is measured using SEM-EDX as follows. Absorb the absorbent article with heat from a dryer, etc., and remove the sheet. Elemental analysis of the sheet surface and the sheet back surface is performed on the extracted sheet using JSM-6510 manufactured by JEOL Ltd. At that time, the ratio W2 / W1 is obtained from the element ratio of the sheet surface to the sheet back surface.
  • various methods such as ESCA and TOF-SIMS can be used alone or in combination.
  • the hemagglutinating agent may be present on the skin facing surface side as long as it is unevenly distributed on the non-skin facing surface side.
  • the region containing the hemagglutinating agent when viewed along the thickness direction of the hemagglutinating sheet includes a non-skin facing surface in the thickness direction. It is preferable that it is the area
  • a solution containing the hemagglutinating agent and having a viscosity of preferably 100 mPa ⁇ s or more when applied is at least a liquid permeable sheet. It is convenient to adopt a method of applying to one side. In this case, the solution can be applied only to one side of the liquid-permeable sheet, or the both sides of the solution are applied so that the amount of the solution applied is less on the other side than on one side. Can be applied.
  • the solution may uniformly penetrate the entire thickness method of the sheet.
  • a relatively large amount of the solution remains on the coated surface side.
  • the solution is dried, and as a result, a relatively large amount of hemagglutinating agent is present on the coated surface side.
  • the viscosity of the solution is more preferably 100 mPa ⁇ s or more, and more preferably 200 mPa ⁇ s or more at the time of application.
  • the upper limit of the viscosity is preferably 500 mPa ⁇ s or less, more preferably 300 mPa ⁇ s or less, and even more preferably 200 mPa ⁇ s or less.
  • absorbent article is disclosed further regarding embodiment of this invention mentioned above.
  • ⁇ 1> A liquid-permeable top sheet disposed on the skin facing surface side, a liquid-impermeable back sheet disposed on the non-skin facing surface side, and an absorbent disposed between these sheets
  • An absorbent article wherein the absorbent body has an absorbent core containing pulp fibers, and a core wrap sheet that has a hole and covers the absorbent core, and the skin facing surface of the absorbent core
  • a water-soluble hemagglutinating agent is arranged on the core wrap sheet covering the side.
  • hemagglutinating agent is held in a state in which the pores of the core wrap sheet are filled, and when the moisture permeates the core wrap sheet, the hemagglutinating agent dissolves and voids in the pores
  • the said hemagglutinating agent is an absorbent article as described in said ⁇ 1> or ⁇ 2> which exists more in the skin opposing surface side of the said core wrap sheet than the non-skin opposing surface side.
  • ⁇ 4> The absorbent article according to any one of ⁇ 1> to ⁇ 3>, wherein the core wrap sheet has a second water permeation rate higher than a first water permeation rate.
  • ⁇ 5> The absorbent article according to ⁇ 4>, wherein the water permeability rate is measured by the following method.
  • the absorbent core contains a superabsorbent polymer, the blending amount of the superabsorbent polymer changes in the thickness direction of the absorbent core, and a pulp layer that contains the pulp fibers and does not contain the superabsorbent polymer
  • the absorbent article according to any one of ⁇ 1> to ⁇ 5>, which is present on the skin facing surface side of the absorbent core.
  • the absorbent core contains a superabsorbent polymer, the blending amount of the superabsorbent polymer changes in the thickness direction of the absorbent core, and a pulp layer that contains the pulp fibers and does not contain the superabsorbent polymer
  • the absorbent article according to any one of ⁇ 1> to ⁇ 6>, wherein the absorbent article is present on the non-skin facing surface side of the absorbent core.
  • ⁇ 8> The absorbent article according to any one of ⁇ 1> to ⁇ 7>, wherein the hemagglutinating agent is also blended in the absorbent core.
  • ⁇ 9> The absorbent article according to any one of ⁇ 1> to ⁇ 8>, wherein an average pore diameter of the absorbent core is larger than an average pore diameter of the core wrap sheet.
  • ⁇ 10> The absorbent article according to any one of ⁇ 1> to ⁇ 9>, wherein an average fiber density of the absorbent core is smaller than an average fiber density of the core wrap sheet.
  • ⁇ 12> The absorbent article according to any one of the above items ⁇ 1> to ⁇ 11>, wherein 10% or more of the volume of the entire gap of the core wrap sheet is filled with the water-soluble hemagglutinating agent.
  • the core wrap sheet has a void portion between fibers, and the void portion has a structure communicating in the thickness direction of the core wrap sheet, and the void between the fibers is formed by the communicated void portion.
  • ⁇ 15> The absorbent article according to any one of ⁇ 1> to ⁇ 14>, wherein the core wrap sheet has an average pore diameter of 10 ⁇ m to 150 ⁇ m.
  • ⁇ 18> The absorption according to any one of ⁇ 1> to ⁇ 17>, wherein the core wrap sheet has a pH of an aqueous extract measured by JIS P 81333-1: 2013 of 3.5 or more and 9.0 or less.
  • ⁇ 19> A liquid-permeable surface sheet disposed on the skin facing surface side, a back sheet disposed on the non-skin facing surface, and an absorber disposed between both sheets, and a longitudinal direction along the wearer's front-rear direction and ⁇ 1> to ⁇ 1> which is an absorbent article for menstrual blood absorption having a transverse direction perpendicular to the longitudinal direction, wherein the topsheet is partially joined to the core wrap sheet.
  • ⁇ 20> The absorbent article according to any one of ⁇ 1> to ⁇ 19>, wherein the core wrap sheet is recessed in a groove shape together with the top sheet.
  • a vertically long absorbent article comprising the top sheet, the back sheet, and the absorber disposed between the two sheets, Any one of the above items ⁇ 1> to ⁇ 20>, wherein the core wrap sheet has a leak-proof groove formed in a groove shape together with the top sheet on the lateral outer side of the excretion facing part facing the excretion part of the wearer 2.
  • seat has the leak-proof groove integrated with the said surface sheet and the said absorptive core in the side part along a vertical direction, and the edge part along a horizontal direction,
  • ⁇ 23> The absorbent article according to ⁇ 22>, wherein the leakproof groove is in a state where its constituent fibers are heat-sealed.
  • ⁇ 24> The absorbent article according to any one of ⁇ 1> to ⁇ 23>, wherein the surface sheet is made of an uneven nonwoven fabric having unevenness on at least a skin facing surface side.
  • ⁇ 25> The absorbent article according to any one of ⁇ 1> to ⁇ 24>, wherein the absorbent core is formed by integral molding.
  • ⁇ 26> The absorbent article according to any one of ⁇ 1> to ⁇ 25>, wherein the absorbent core contains a superabsorbent polymer.
  • ⁇ 27> The absorbent article according to any one of ⁇ 1> to ⁇ 26>, wherein a deodorant or an antibacterial agent is blended in the absorbent core.
  • ⁇ 28> The absorbent article according to any one of ⁇ 1> to ⁇ 27>, wherein the absorbent article has a pair of wing portions on both side portions in the longitudinal direction corresponding to the wearer's front-rear direction.
  • ⁇ 29> The absorbent article according to any one of ⁇ 1> to ⁇ 28>, further comprising a rear flap portion in a lateral rear portion of the rear portion.
  • ⁇ 30> The absorbent article according to any one of the above items ⁇ 1> to ⁇ 29>, further comprising a three-dimensional guard that can stand toward the wearer on both left and right sides along the front-rear direction.
  • ⁇ 31> The absorbent article according to any one of the above items ⁇ 1> to ⁇ 30>, wherein an adhesive is partially applied to a part of the absorbent article that contacts the undergarment of the back sheet.
  • ⁇ 32> The absorbent article according to any one of ⁇ 1> to ⁇ 31>, wherein the hemagglutinating agent has a property of starting dissolution within 3 minutes from the time of contact with physiological saline.
  • An absorbent article wherein the absorbent body has an absorbent core containing pulp fibers, and a core wrap sheet that has a hole and covers the absorbent core, and the skin facing surface of the absorbent core
  • a water-soluble cationic polymer is held in a state in which the pores of the core wrap sheet are filled, and when moisture passes through the core wrap sheet, An absorbent article in which the cationic polymer is dissolved to increase the voids in the pores.
  • ⁇ 34> A hemagglutinating agent having a relatively large amount of one side of the core wrap sheet as the covering sheet for covering the absorbent core on the skin-facing surface side of the core wrap sheet as compared to the other side.
  • the core wrap sheet has a mass ratio W2 / W1 between the amount W1 of the hemagglutinating agent contained on the one side and the amount W2 of the hemagglutinating agent contained on the other side.
  • the absorbent article according to ⁇ 34> which is in the range of / 100 to 27/73.
  • ⁇ 36> The absorbent article according to ⁇ 34> or ⁇ 35>, wherein the hemagglutinating agent is made of a cationic polymer having a weight average molecular weight of 150,000 or more.
  • ⁇ 38> The absorbent article according to any one of ⁇ 34> to ⁇ 37>, wherein the core wrap sheet is made of paper.
  • Example 1 A sanitary napkin having the form shown in FIGS. 1 and 2 was prepared and used as a sample of Example 1.
  • the sanitary napkin had a thickness of 1.9 mm.
  • the absorbent body 4 is configured to wrap the absorbent core 41 in a single core wrap sheet 42 from the skin facing surface side to the non-skin facing surface side.
  • the surface sheet 2 a non-woven fabric used in Laurie Skin Clean Guard (normal wings) manufactured by Kao Corporation was used.
  • the back sheet 3 a non-moisture permeable resin film was used.
  • the absorbent core 41 includes a laminated absorbent core in which a mixed fiber containing wood pulp fibers and a superabsorbent polymer is disposed on the skin facing surface, and an absorbent core made of only wood pulp fibers is disposed on the non-skin facing surface.
  • the mixed fiber body had a wood pulp fiber basis weight of 100 g / m 2 and a superabsorbent polymer basis weight of 56 g / m 2 .
  • the superabsorbent polymer a general-purpose grade superabsorbent polymer for sanitary goods manufactured by Nippon Shokubai Co., Ltd. was used.
  • the core wrap sheet 42 As the core wrap sheet 42, a thin paper having a basis weight of 16 g / m 2 and a thickness of 0.3 mm was used. 5.00 g of the hemagglutinating agent having the following formulation is dissolved in 100 g of ion exchange water, and a solution containing the hemagglutinating agent is immersed in the core wrap sheet so as to have a basis weight of 120 g / m 2. The sheet 42 was dried by leaving it in a dryer at 60 ° C. for 24 hours, and the hemagglutinating agent contained in the dried core wrap sheet was 6 g / m 2 .
  • the viscosity at the time of impregnation of the solution containing a hemagglutinating agent was 4.0 mPa ⁇ s.
  • the cationic polymer contained in the hemagglutinating agent include polydiallyldimethylammonium chloride, a water-soluble quaternary ammonium salt homopolymer (trade name Marcoat 106 manufactured by Nippon Lubrizol Co., Ltd. (weight average molecular weight: 15,000). ) was used.
  • the core wrap sheet 42 has an initial permeation rate of 0.28 g / sec, a second permeation rate of 1.15 g / sec, and a ratio between the second permeation rate and the first permeation rate (second permeation rate / first permeation rate). Speed) was 4.1.
  • the core wrap sheet 42 had more hemagglutinating agent on the skin facing surface side.
  • the average hole diameter of the absorptive core was larger than the average hole diameter of the core wrap sheet.
  • Example 4 in Example 1, the absorbent core 41 uses a mixed fiber containing wood pulp fibers and a superabsorbent polymer, and a single fiber layer that does not contain a superabsorbent polymer.
  • the prescription was the same as in Example 1 except that the skin-facing surface was changed.
  • the average pore diameter of the absorbent core was larger than the average pore diameter of the core wrap sheet.
  • Example 3 A sanitary napkin was prepared in the same manner as in Example 1 except that the prescription of the hemagglutinating agent was replaced as follows.
  • Example 3 Polydiallyldimethylammonium chloride obtained by drying trade name PAS-H-5L manufactured by Nitto Bo Medical Co., Ltd.
  • Example 4 Polydiallyldimethylammonium chloride obtained by drying the trade name Marcoat 100 manufactured by Nippon Lubrizol Co., Ltd., weight average molecular weight 150,000, streaming potential 7488 ⁇ eq / L, IOB 2.1)
  • Example 5 Poly (diallyldimethylammonium chloride) obtained by drying a poly (diallyldimethylammonium chloride) solution manufactured by Aldrich (weight average molecular weight: 400,000 to 500,000, streaming potential 6827 ⁇ eq / L, IOB 2.1 )
  • ⁇ Comparative Example 1> A sanitary napkin was prepared in the same manner as in Example 1 except that a core wrap sheet that did not retain the hemagglutinating agent was used, and this was used as a sample of Comparative Example 1. The thickness of the sanitary napkin is 1.9 mm.
  • ⁇ Comparative Example 2> A cored wrap sheet that does not retain the hemagglutinating agent is used, and the absorbent core has a basis weight of wood pulp fibers of 300 g / m 2 and a superabsorbent polymer basis weight of 15 g / m 2.
  • a sanitary napkin having a thickness of 4.2 mm was prepared in the same manner as in Example 1 except that was used as a sample of Comparative Example 2.
  • FIG. 7A shows an electron microscope (SEM) photograph of the core wrap sheet used in Examples 1 and 2 before the hemagglutinating agent is applied
  • FIG. 7B shows the hemagglutinating agent applied
  • FIG. 7C shows an electron microscope (SEM) photograph of the core wrap sheet used in Examples 1 and 2 after being applied. Example in which the hemagglutinating agent is held in a state in which the pores are filled
  • SEM electron microscope
  • a sample of a sanitary napkin was fixed to a sanitary short and attached to a dynamic model of the human body.
  • the walking motion of the dynamic model was started, and 1 g after the start of the walking motion, 2 g of pseudo blood was injected from the excretory part facing part (first time). Furthermore, 3 g of simulated blood was injected 3 minutes after the end of the first liquid injection (second time). Furthermore, 2 g of simulated blood was injected 3 minutes after the end of the second liquid injection (third time).
  • the third and subsequent liquid injections were repeatedly injected with 2 g of pseudo blood 3 minutes after the liquid injection, and ended when the liquid oozed out from the wing part of the sanitary napkin, and the dynamic maximum absorption amount was obtained.
  • the simulated blood was measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) as described in this specification.
  • the blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories Co., Ltd.) was prepared so that the viscosity obtained was 8 mPa ⁇ s.
  • ⁇ Wet back amount> Place the sanitary napkin sample horizontally with the top sheet facing the top, and place a cylindrical acrylic plate with a 1 cm diameter injection port on the bottom, and inject 6 g of simulated blood from the injection port. The state was maintained for 1 minute. Next, the acrylic plate with a cylinder was removed, and 16 sheets of absorbent paper (commercially available tissue paper) having a length of 6 cm ⁇ width of 9.5 cm and a basis weight of 13 g / m 2 were placed on the surface of the surface sheet. Further, a weight was placed thereon so that the pressure was 20 ⁇ 98 Pa (20 gf / cm 2 ), and pressure was applied for 5 seconds.
  • absorbent paper commercially available tissue paper
  • the absorbent paper After pressurization, the absorbent paper was taken out, and the weight of the absorbent paper after pressurization was measured. By subtracting the weight of the absorbent paper before pressurization from the weight of the absorbent paper after pressurization, the mass of simulated blood absorbed by the paper was calculated and used as the surface liquid return amount.
  • the core wrap sheet used in Examples 1 and 2 is maintained in a state in which the hemagglutinating agent fills the pores, and the core wrap sheet has moisture.
  • the hemagglutinating agent retained in a state where the pores were filled was dissolved, and the voids in the pores increased.
  • the sanitary napkin of Example 1 and Example 2 had an increased dynamic maximum absorption amount and a reduced wetback amount as compared with the sanitary napkin of Comparative Example 1. The absorption performance is improved.
  • the sanitary napkin of Example 1 is a product compared to the sanitary napkin of Comparative Example 2.
  • Example 1 and Example 2 are compared, the amount of wetback is smaller in Example 2.
  • positioned the fiber single layer which does not contain a superabsorbent polymer in the skin opposing surface side is expressed more highly.
  • the absorbent article of this invention it turns out that the improvement effect of the absorption performance by a hemagglutinating agent is expressed effectively, and the outstanding absorption performance is show
  • Example 1 except that the basis weight of the wood pulp fiber was changed to 280 g / m 2 and the basis weight of the superabsorbent polymer was changed to 29 g / m 2 for the mixed core fiber of the absorbent core used in Examples 1 to 5.
  • a sanitary napkin having a thickness of 4.2 mm was prepared. The dynamic maximum absorption amount and the wetback amount were measured by the methods described above and are shown in Table 3.
  • Comparative Example 3 The mixed fiber of the absorbent core used in Comparative Example 1 was the same as Comparative Example 1 except that the basis weight of the wood pulp fiber was changed to 280 g / m 2 and the basis weight of the superabsorbent polymer was changed to 29 g / m 2.
  • a sanitary napkin having a thickness of 4.2 mm was prepared. The dynamic maximum absorption amount and the wetback amount were measured by the methods described above and are shown in Table 3.
  • a sanitary napkin that does not contain a hemagglutinating agent is used to suppress the dynamic maximum absorption amount and the liquid return amount even with a “normal slim type” sanitary napkin having a thickness of 4.2 mm. It can be seen that this is an improvement over 3).
  • the present invention is very effective in that the absorbent article is thinned to improve the feeling of wear while improving the feeling of wear, but as in Examples 6 to 10. This is also effective in improving the liquid absorption performance of a thick absorbent article.
  • Pulp paper with a basis weight of 25 g / m 2 Pulp: Caribbean type, thickness: 0.326 mm (at 0.5 g / cm 2 load), bulk density at 0.5 g / cm 2 load: 0.08 g / cm 3 )
  • a hemagglutinating agent was applied on one side.
  • polydiallyldimethylammonium chloride Nippon Lubrizol Corporation, trade name “Mercoat 100”, weight average molecular weight 150,000
  • hemagglutinating agent polydiallyldimethylammonium chloride (Senka Co., Ltd., trade name “Unisense FPA1002L”, weight average molecular weight 600,000) which is a water-soluble quaternary ammonium salt homopolymer was used. 10 g of the hemagglutinating agent was dissolved in 55.6 g of water to prepare a solution having a viscosity of 749 mPa ⁇ s. This solution was applied to the same paper as the paper used in Test Example 1 with a brush so as to have a basis weight shown in Table 5 below. Thus, a hemagglutinating sheet was obtained.
  • hemagglutinating agent water-soluble quaternary ammonium salt homopolymer polydimethylaminoethyl diethyl sulfate sulfate (Kao Corporation, trade name “Kaosela MD-P”, weight average molecular weight 56,000) is used. It was. 10 g of the hemagglutinating agent was dissolved in 27.8 g of water to prepare a solution having a viscosity of 189 mPa ⁇ s. This solution was applied to the same paper as the paper used in Test Example 1 with a brush so as to have a basis weight shown in Table 5 below. Thus, a hemagglutinating sheet was obtained.
  • the liquid permeability of the hemagglutinating sheet was evaluated using this amount as a scale.
  • the simulated blood is measured using a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds).
  • the blood cell / plasma ratio of defibrinated horse blood (manufactured by Nippon Biotest Co., Ltd.) is adjusted so that the measured viscosity is 8 mPa ⁇ s.
  • the term “pseudoblood” is used in this sense.
  • the lid was removed, and an excess amount of simulated blood was absorbed and removed using absorbent paper. Subsequently, the diameter of the superabsorbent polymer was measured with an optical microscope.
  • the volume swelling ratio is defined by (R 2 / R 1 ) 3 .
  • a larger value of the volume swelling ratio means that the superabsorbent polymer has absorbed a larger amount of liquid.
  • the hemagglutinating sheet obtained in each test example had a volume swelling ratio of the superabsorbent polymer that was comparable.
  • the volume swelling rate of the superabsorbent polymer when evaluated in the same manner as in Test Example 1 without adding a hemagglutinating agent is 12.2 times.
  • the hemagglutinating sheet in which the hemagglutinating agent is unevenly distributed on the non-skin facing surface side is compared with the sheet in which the hemagglutinating agent is unevenly distributed on the skin facing surface side. It can be seen that the increase in the volume of swelling of the superabsorbent polymer can be achieved without increasing the amount of simulated blood permeated for 20 seconds. It can also be seen that the degree of decrease in the permeation amount of the liquid is small while maintaining the absorption amount of the pseudo blood.
  • the hemagglutinating sheet in which the hemagglutinating agent is unevenly distributed on the skin-facing surface side has a volume swelling of the superabsorbent polymer although the permeation amount of the pseudo blood decreases as the number of times increases.
  • the magnification is as good as that of the hemagglutinating sheet in which the hemagglutinating agent is unevenly distributed on the non-opposing surface side. That is, even when such a hemagglutinating sheet is used for a napkin, it is suggested that the plasma component can be sufficiently absorbed by the superabsorbent polymer of the absorbent core through the hemagglutinating sheet.
  • the absorbent article of the present invention the effect of improving the absorption performance due to the hemagglutination action of the hemagglutinating agent or cationic polymer is effectively expressed, and excellent absorption performance is exhibited.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

La présente invention concerne un article absorbant (1) qui comporte une feuille de surface perméable aux fluides (2), une feuille arrière imperméable aux fluides (3), et un absorbeur (4) disposé entre les deux feuilles. L'absorbeur (4) comporte un noyau absorbant (41) qui comprend une fibre de pâte, et une feuille d'enveloppe de noyau (42) qui comporte des vides et recouvre le noyau absorbant (41). Un agent d'hémagglutination hydrosoluble est disposé dans la feuille d'enveloppe de noyau (42) qui recouvre un côté de surface côté peau du noyau absorbant (41). L'agent d'hémagglutination est maintenu de façon à remplir les vides de la feuille d'enveloppe de noyau (42) et, lorsque l'humidité traverse dans la feuille d'enveloppe de noyau (42), l'agent d'hémagglutination se dissout de façon à augmenter favorablement les espacements dans les vides.
PCT/JP2017/019967 2016-06-03 2017-05-29 Article absorbant WO2017209072A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780016535.XA CN108778206A (zh) 2016-06-03 2017-05-29 吸收性物品

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2016-111620 2016-06-03
JP2016111620A JP6228629B1 (ja) 2016-06-03 2016-06-03 吸収性物品
JP2016-112109 2016-06-03
JP2016112109 2016-06-03
JP2017-103981 2017-05-25
JP2017103981A JP6887878B2 (ja) 2016-06-03 2017-05-25 吸収性物品

Publications (1)

Publication Number Publication Date
WO2017209072A1 true WO2017209072A1 (fr) 2017-12-07

Family

ID=60478051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/019967 WO2017209072A1 (fr) 2016-06-03 2017-05-29 Article absorbant

Country Status (1)

Country Link
WO (1) WO2017209072A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2011136079A (ja) * 2009-12-28 2011-07-14 Livedo Corporation 吸収性物品および吸収性物品包装体
JP2011520532A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー カチオン性化工デンプンを含む吸収性製品
JP2011529772A (ja) * 2008-08-08 2011-12-15 ザ プロクター アンド ギャンブル カンパニー カチオン性変性グアーガムを含む吸収性製品
JP2013040434A (ja) * 2011-07-19 2013-02-28 Kao Corp 薄葉紙の製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
JP2011520532A (ja) * 2008-05-19 2011-07-21 ザ プロクター アンド ギャンブル カンパニー カチオン性化工デンプンを含む吸収性製品
JP2011529772A (ja) * 2008-08-08 2011-12-15 ザ プロクター アンド ギャンブル カンパニー カチオン性変性グアーガムを含む吸収性製品
JP2011136079A (ja) * 2009-12-28 2011-07-14 Livedo Corporation 吸収性物品および吸収性物品包装体
JP2013040434A (ja) * 2011-07-19 2013-02-28 Kao Corp 薄葉紙の製造方法

Similar Documents

Publication Publication Date Title
WO2017209071A1 (fr) Article absorbant
JP2017217465A (ja) 吸収性物品
JP2017217071A (ja) 生理用吸収性物品
WO2017209068A1 (fr) Article absorbant
JP6259540B2 (ja) 生理用吸収性物品
JP2018007705A (ja) 生理用吸収性物品
JP6279015B2 (ja) 吸収性物品
JP2017217066A (ja) 吸収性物品
JP2017217069A (ja) 生理用吸収性物品
JP6887878B2 (ja) 吸収性物品
WO2017209076A1 (fr) Article absorbant hygiénique
WO2017209069A1 (fr) Article absorbant
WO2017209072A1 (fr) Article absorbant
TW201801696A (zh) 吸收性物品
JP6762142B2 (ja) 吸収性物品
JP6259539B2 (ja) 生理用吸収性物品
WO2017110716A1 (fr) Article absorbant
TW201801690A (zh) 吸收性物品
JP2019041794A (ja) 吸収性物品
JP6220947B1 (ja) 生理用品
JP6949662B2 (ja) 吸収性物品
JP6228630B1 (ja) 血球凝集性繊維
WO2017209070A1 (fr) Élément absorbant
JP6228705B1 (ja) 血球凝集性繊維
WO2017209074A1 (fr) Article absorbant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17806627

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17806627

Country of ref document: EP

Kind code of ref document: A1